Lercanidipin Accord (Lercanidipine)

Lercanidipine is indicated for the management of hypertension, acting on the vascular smooth‑muscle calcium channels to lower blood pressure.

• Hypertension: reduces systolic and diastolic blood pressure in adults.
• Primary hypertension: helps achieve guideline‑recommended blood pressure targets.
• Isolated systolic hypertension: provides effective control of elevated systolic pressure.

• Lercanidipine selectively antagonizes L‑type calcium channels in vascular smooth muscle. By blocking calcium entry, it prevents contraction of the arterial wall, leading to vasodilation, decreased peripheral vascular resistance, and ultimately a reduction in systemic blood pressure.

Lercanidipine may be associated with several adverse reactions. Patients should be aware of both frequent and rare events.

Common Side Effects

• Headache: mild to moderate pain often occurring shortly after initiation.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness: sensation of light‑headedness, especially when standing quickly.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or throat requiring immediate medical attention.
• Severe hypotension: marked drop in blood pressure that can cause fainting.
• Hepatic dysfunction: abnormal liver enzyme elevations or hepatitis.

Before prescribing Lercanidipine, clinicians should consider several safety aspects.

• Blood pressure monitoring: check baseline and follow‑up readings to avoid excessive hypotension.
• Cardiovascular assessment: evaluate for heart failure or recent myocardial infarction.
• Hepatic impairment: use with caution in patients with liver disease.
• Concomitant antihypertensives: adjust doses to prevent additive blood pressure lowering.
• Abrupt discontinuation: taper gradually to avoid rebound hypertension.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Lercanidipine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels.
• Concurrent use with other potent antihypertensives: risk of severe hypotension.
• Grapefruit juice: enhances drug exposure and can precipitate adverse effects.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness.

• Diuretics: may increase risk of electrolyte imbalance.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can attenuate blood pressure‑lowering response.